She already worked at EMA from 2002 to 2016 and has 30 years of experience in international regulatory affairs. Top priority will be given to the development and approval of safe and effective drugs and vaccines against Covid-19. In addition to the current situation, which she described as a "public health crisis of unprecedented scale", she names the following impending challenges:
Write a comment on this news.